Compugen Ltd. (CGEN)

NCM – Real vaqt narxi. Valyuta: USD

2.83

-0.04 (-1.39%)

Yopilishda: May 12, 2026, 4:00 PM EDT

04.05.2026

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its first quarter 2026 financial results on Monday, May 18, 2026, before the U.S. financial markets open.

09.04.2026

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

HOLON, Israel, April 9, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference.

02.03.2026

Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Compugen remains a 'Buy,' supported by pipeline progress, major pharma partnerships, and a cash runway extended into 2029. Key catalysts include the phase 3 MAIA-Ovarian cancer trial (COM701), with interim analysis expected in Q1 2027, and the anti-IL18BP antibody GS-0321 in phase 1. CGEN's non-dilutive deal with AstraZeneca monetizes rilvegostomig royalties, enhancing financial stability and preserving future upside.

02.03.2026

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

02.03.2026

Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates

Compugen (CGEN) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to a loss of $0.07 per share a year ago.

02.03.2026

Compugen Reports Fourth Quarter and Full Year 2025 Results

Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029 Enhanced leadership team with Dr. Eran Ophir appointed President and CEO and Dr. Anat Cohen-Dayag transitioned to Executive Chair Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively On track to have MAIA-ovarian interim analysis in Q1 2027 Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with 10 ongoing Phase 3 clinical trials, and anticipates further Phase 1/2 clinical trial data with rilvegostomig in 2026 HOLON, ISRAEL, March 2, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today reported financial results for the fourth quarter and full year 2025 and provided a corporate update.

19.02.2026

Compugen to Participate in Upcoming Investor Conferences

HOLON, Israel, Feb. 19, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Location: Virtual Format: Fireside chat and 1x1 meetings Fireside chat time: 2 PM ET Leerink Partners 2026 Global Healthcare Conference Date: Monday, March 9, 2026 Location: Miami, Florida, U.S. Format: Fireside chat and 1x1 meetings Fireside chat time: 8:40 AM ET Live webcasts of the fireside chats will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com.

Videolar

No Data

There is no data to display

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

HOLON, Israel, Feb. 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced the appointment of Michele Holcomb, Ph.D.

17.12.2025

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Non-dilutive strategic transaction expected to extend cash runway into 2029, to advance Compugen's innovative immuno-oncology pipeline and to reach potential key catalysts from internal and partnered programs Monetization includes an upfront payment of $65 million and a potential additional $25 million upon reaching the next milestone Compugen retains majority of royalties preserving potential significant long-term upside reflecting its belief in the potential of rilvegostomig HOLON, Israel , Dec. 17, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today announced that it has agreed with AstraZeneca to monetize a portion of Compugen's rilvegostomig future royalties.

Compugen Ltd. (CGEN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Compugen Ltd. (CGEN)

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen to Participate in Upcoming Investor Conferences

Videolar

No Data

Press-relizlar

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen to Participate in Upcoming Investor Conferences

Videolar

No Data

Press-relizlar

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Search stocks

Compugen Ltd. (CGEN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Compugen Ltd. (CGEN)

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen to Participate in Upcoming Investor Conferences

Videolar

No Data

Press-relizlar

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen to Participate in Upcoming Investor Conferences

Videolar

No Data

Press-relizlar

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million